共 50 条
- [32] Aurora kinase A inhibitor, LY3295668 erbumine: a phase 1 monotherapy safety study in patients with locally advanced or metastatic solid tumorsINVESTIGATIONAL NEW DRUGS, 2021, 39 (04) : 1001 - 1010Chu, Quincy Siu-chungBouganim, NathanielFortier, CarolineZaknoen, SaraStille, John R.Kremer, Jill D.Yuen, EuniceHui, Yu-Huade la Pena, AmparoLithio, AndrewSmith, Patricia S.Batist, Gerald
- [33] Aurora kinase A inhibitor, LY3295668 erbumine: a phase 1 monotherapy safety study in patients with locally advanced or metastatic solid tumorsInvestigational New Drugs, 2021, 39 : 1001 - 1010Quincy Siu-chung ChuNathaniel BouganimCaroline FortierSara ZaknoenJohn R. StilleJill D. KremerEunice YuenYu-Hua HuiAmparo de la PeñaAndrew LithioPatricia S. SmithGerald Batist
- [34] Trial in progress: A phase 1/2 study of ASP1570, a novel inhibitor of DGKζ, in participants with locally advanced or metastatic solid tumors who have progressed on, or are ineligible for, all available standard therapiesCANCER RESEARCH, 2023, 83 (08)Patel, Manish R.Park, David J.Tarantolo, StefanoDowlati, AfshinOlson, DanielKaneko, YuichiroTang, MeiSoukharev, SergueiTakizawa, MasaomiOkada, YoheiFredericks, ChristineFlegel, TeresaWatanabe, TsubasaLee, SueLuke, Jason John
- [35] Safety and efficacy of ifebemtinib (IN10018) combined with D-1553 in solid tumors with KRAS G12C mutation: Results from a phase Ib/II studyANNALS OF ONCOLOGY, 2024, 35 : S497 - S498Song, Z.Li, X.Liu, Y.Yuan, Y.Lin, R.Shi, H.Luo, Y.Lv, T.Zhang, Y.Zhu, L.Zhu, Y.Xie, S.Zhang, B.Wang, Z.
- [36] A FIRST-IN-HUMAN PHASE I STUDY OF M6223 (TIGIT INHIBITOR) AS MONOTHERAPY OR IN COMBINATION WITH BINTRAFUSP ALFA IN PATIENTS WITH METASTATIC OR LOCALLY ADVANCED SOLID UNRESECTABLE TUMORSJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A561 - A561Watson, GeoffreyMcKean, MeredithTolcher, AnthonyVictor, AnjaZhang, SenPierre, VadrynRichter, EmiliaNaing, AungNaing, Aung
- [37] CodeBreaK 200: A Phase 3 Multicenter Study of Sotorasib, a KRAS(G12C) Inhibitor, versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring KRAS p.G12C MutationJOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S29 - S29Reck, M.Spira, A.Besse, B.Wolf, J.Skoulidis, F.Borghaei, H.Goto, K.Park, K.Griesinger, F.Font, E. F.Boyer, M.Barrios, C. H.Goss, G.Yang, H.Obiozor, C.Ramalingam, S.
- [38] Phase II study of refametinib (BAY 86-9766), an allosteric dual MEK 1/2 inhibitor, and gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer.JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Van Laethem, Jean-LucJassem, JacekHeinemann, VolkerWeekes, Colin D.Bridgewater, John A.Cascinu, StefanoMelichar, BohuslavPeeters, MarcRoss, Paul J.Saramak, PiotrGiurescu, MariusGarosi, Vittorio LuigiRoth, KatrinSchulz, AnkeTeufel, MichaelChilds, Barrett H.Riess, Hanno
- [39] KRAS G12C Inhibitor IBI351 In Patients (pts) with Advanced Non-Small Cell Lung Cancer (NSCLC): Updated Results from a Pivotal Phase 2 StudyJOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S42 - S42Zhou, Q.Meng, X.Sun, L.Huang, D.Yang, N.Yu, Y.Zhao, M.Zhuang, W.Hu, Y.Pan, Y.Sun, M.Shan, J.Guo, R.Chu, Q.Xu, C.Lin, J.Huang, J.Huang, M.Zhang, S.Wu, Y. L.
- [40] MOONRAY-01, a phase 1 study of LY3962673, a potent, orally bioavailable, and selective KRAS G12D inhibitor in KRAS G12D-mutant solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : TPS845 - TPS845Lakhani, Nehal J.Melisi, DavideSubbiah, VivekAmmakkanavar, Natraj ReddyO'Reilly, Eileen M.Cassier, Philippe AlexandreWainberg, Zev A.Duffy, Austin G.Patnaik, AmitaFujiwara, YutakaOberstein, Paul EliezerGarcia-Carbonero, RocioWright, JenniferLin, Aimee K.Li, JianAxelson, Michael D.Garrido-Laguna, Ignacio